Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) EBT: 2011-2025

Historic EBT for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to -$623,000.

  • Fennec Pharmaceuticals' EBT rose 89.09% to -$623,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.4 million, marking a year-over-year decrease of 588.35%. This contributed to the annual value of -$71,000 for FY2024, which is 99.56% up from last year.
  • Per Fennec Pharmaceuticals' latest filing, its EBT stood at -$623,000 for Q3 2025, which was up 80.25% from -$3.2 million recorded in Q2 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' EBT peaked at $12.9 million during Q1 2024, and registered a low of -$10.3 million during Q4 2022.
  • Its 3-year average for EBT is -$1.9 million, with a median of -$2.6 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Fennec Pharmaceuticals' EBT was 316.58% (2024), while the steepest drop was 222.47% (2024).
  • Over the past 5 years, Fennec Pharmaceuticals' EBT (Quarterly) stood at -$4.2 million in 2021, then crashed by 89.66% to -$10.3 million in 2022, then surged by 74.66% to -$2.6 million in 2023, then skyrocketed by 42.67% to -$1.5 million in 2024, then skyrocketed by 89.09% to -$623,000 in 2025.
  • Its last three reported values are -$623,000 in Q3 2025, -$3.2 million for Q2 2025, and -$1.2 million during Q1 2025.